Christopher Ting is a Respiratory physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 19 Jul 2022.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
80.7%Corticosteroid38.9%Trelegy Ellipta45%Symbicort29%Budesonide-Formoterol Fumarate14%Breyna13%Part D<11 patientsbeta2-Adrenergic Agonist28.4%Albuterol Sulfate Hfa79%Ventolin Hfa21%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
10.5%Corticosteroid10.5%Prednisone100%Part D≥13 patientsDermatology
4.6%Polyene Antifungal4.6%Nystatin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- The Role of Transitional Epithelial CCN1 (Cyr61) in Lung Fibrosis
University of Michigan at Ann Arbor
FY2026$168,911K08HL179499 - Regulation and Mechanisms of Transitional Epithelial Cell Senescence in Lung Fibrosis
University of Michigan at Ann Arbor
FY2025$43,982F32HL172379 - Regulation and Mechanisms of Transitional Epithelial Cell Senescence in Lung Fibrosis
University of Michigan at Ann Arbor
FY2024$86,488F32HL172379
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”